Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MTX-474-S101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-474 in Healthy Adults

Trial Profile

MTX-474-S101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-474 in Healthy Adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MTX-474 (Primary)
  • Indications Fibrosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Mediar Therapeutics
  • Most Recent Events

    • 07 Aug 2024 According to a Mediar Therapeutics media release, company announced the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-474.
    • 02 Aug 2024 Status changed from planning to recruiting.
    • 06 May 2024 According to a Mediar Therapeutics media release, initiation of this Phase 1 study is anticipated in Q3-2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top